keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrin neoplasm

keyword
https://www.readbyqxmd.com/read/29787363/nonepithelial-neoplasms-of-the-pancreas-part-2-malignant-tumors-and-tumors-of-uncertain-malignant-potential
#1
Maria A Manning, Edina E Paal, Amogh Srivastava, Koenraad J Mortele
Almost all neoplasms of the pancreas are derived from pancreatic epithelial components, including the most common pancreatic mass, primary pancreatic ductal adenocarcinoma (PDAC). Nonepithelial neoplasms comprise only 1%-2% of all pancreatic neoplasms. Although some may arise directly from intrapancreatic elements, many originate from mesenchymal, hematopoietic, or neural elements in the retroperitoneal peripancreatic space and grow into the pancreas. Once these tumors reach a certain size, it can be challenging to identify their origin...
May 25, 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29769293/emerging-multitarget-tyrosine-kinase-inhibitors-in-the-treatment-of-neuroendocrine-neoplasms
#2
Federica Grillo, Tullio Florio, Francesco Ferraù, Elda Kara, Giuseppe Fanciulli, Antongiulio Faggiano, Annamaria A L Colao
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multi-target tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by regulatory agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in depth review on the studies published on the following MTKIs in neuroendocrine tumours: axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed...
May 16, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29752349/paediatric-pancreatic-neuroendocrine-tumours-in-von-hippel-lindau-disease
#3
Samuel Matthew O'Toole, Anju Sahdev, Satya Bhattacharya, Roger Feakins, Evelien F Gevers, William Drake
Extract: Pancreatic neuroendocrine tumours (pNETs) are an established feature of von Hippel-Lindau disease (VHL), occurring in up to 17% of mutation carriers (Libutti et al. 2000; Blansfield et al. 2007; Erlic et al. 2010; Igarashi et al. 2014). The natural history of VHL-pNETs is poorly characterised with metastatic disease occurring in up to 25% of affected individuals (Erlic et al. 2010). Management of this unique pNET subgroup is complicated by the potential for multifocal and metachronous disease as well as extra-pancreatic VHL-related neoplasms (e...
May 11, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29746922/diabetes-and-pancreatic-neuroendocrine-tumours-which-interplays-if-any
#4
REVIEW
Marco Gallo, Rosaria Maddalena Ruggeri, Giovanna Muscogiuri, Genoveffa Pizza, Antongiulio Faggiano, Annamaria Colao
Pancreatic neuroendocrine tumours (PanNETs) represent an uncommon type of pancreatic neoplasm, whose incidence is increasing worldwide. As per exocrine pancreatic cancer, a relationship seems to exist between PanNETs and glycaemic alterations. Diabetes mellitus (DM) or impaired glucose tolerance often occurs in PanNET patients as a consequence of hormonal hypersecretion by the tumour, specifically affecting glucose metabolism, or due to tumour mass effects. On the other hand, pre-existing DM may represent a risk factor for developing PanNETs and is likely to worsen the prognosis of such patients...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29739948/a-meta-analysis-of-prognostic-factor-of-pancreatic-neuroendocrine-neoplasms
#5
Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao
Pancreatic neuroendocrine neoplasms (pNENs) are a group of clinically rare and heterogeneous diseases of the pancreas. However, the prognostic factors for this disease in patients still remain controversial. The purpose of our study is to evaluate the predictive roles of those prognostic factors for pNENs. All related articles published until Sep 17, 2017 were identified via PubMed, EMBASE, Web of Science, Ovid and the Cochrane Library. Studies that examined the prognostic factors of pNENs were enrolled. 17 articles (2822 patients) were finally included in this study...
May 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29727904/endoscopic-ultrasound-guided-radiofrequency-ablation-for-management-of-benign-solid-pancreatic-tumors
#6
Jun-Ho Choi, Dong-Wan Seo, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim
BACKGROUND:  Radiofrequency ablation (RFA) has been increasingly employed in experimental and clinical settings for the management of pancreatic lesions. This study aimed to assess the safety and efficacy of endoscopic ultrasound (EUS)-guided RFA for benign solid pancreatic tumors. METHODS:  In a single-center, prospective study, 10 patients with benign solid pancreatic tumors underwent EUS-RFA. After the RFA electrode had been inserted into the pancreatic mass, the radiofrequency generator was activated to deliver 50 W of ablation power...
May 4, 2018: Endoscopy
https://www.readbyqxmd.com/read/29723285/vasostatin-1-a-novel-circulating-biomarker-for-ileal-and-pancreatic-neuroendocrine-neoplasms
#7
Andrea Corsello, Luigi Di Filippo, Sara Massironi, Federica Sileo, Anna Dolcetta Capuzzo, Marco Gemma, Claudia Carlucci, Claudio Cusini, Barbara Colombo, Alice Dallatomasina, Giulia Maria Franchi, Angelo Corti, Marco Federico Manzoni
BACKGROUND: Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as a tumor biomarker is relatively low because plasma CgA can increase also in patients with other diseases or in subjects treated with proton-pump inhibitors (PPIs), a class of widely-used drugs. METHODS: In the attempt to identify a more reliable biomarker for NENs, we investigated, by ELISA, the circulating levels of full-length CgA (CgA1-439) and of various CgA-derived fragments in 17 patients with ileal or pancreatic NENs, 10 healthy controls, and 21 healthy volunteers before and after treatment with PPIs...
2018: PloS One
https://www.readbyqxmd.com/read/29696624/therapeutic-targeting-of-tumor-associated-macrophages-in-pancreatic-neuroendocrine-tumors
#8
Sebastian Krug, Rami Abbassi, Heidi Griesmann, Bence Sipos, Dominik Wiese, Peter Rexin, Annika Blank, Aurel Perren, Johannes Haybaeck, Stefan Hüttelmaier, Anja Rinke, Thomas M Gress, Patrick Michl
Pancreatic neuroendocrine tumors (PNETs) represent a heterogeneous group of neuroendocrine neoplasms with varying biological behaviour and response to treatment. Although targeted therapies have been shown to improve the survival for patients at advanced stage, resistance to current therapies frequently occurs during the course of therapy. Previous reports indicate that the infiltration of tumor-associated macrophages (TAMs) in PNETs might correlate with tumor progression and metastasis formation. We aimed to evaluate the prognostic and functional impact of TAMs in human PNETs in vitro and in vivo and to investigate the effect of therapeutic targeting TAMs in a genetic PNET mouse model...
April 26, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29696066/metastatic-neuroendocrine-pancreatic-tumor-case-report
#9
E C Radu, A I Saizu, R R Grigorescu, A E Croitoru, C Gheorghe
Rationale. Pancreatic neuroendocrine tumors (NETs) are rare neoplasms that develop from the endocrine tissues of the pancreas. They have a better overall prognosis than pancreatic adenocarcinoma. However, all commonly used classification systems reflect a separation between more indolent, well-differentiated tumors and far more aggressive poorly differentiated types that behave clinically more like small-cell carcinoma of the lung. Objective. To present the case of a 62-year-old man with an aggressive pancreatic NET, with liver, splenic and bone metastases who underwent multidisciplinary treatment including several lines of chemotherapy, somatostatin analogs and radiotherapy...
January 2018: Journal of Medicine and Life
https://www.readbyqxmd.com/read/29683974/pancreatic-neuroendocrine-tumors-and-intraductal-papillary-mucinous-neoplasm-of-the-pancreas-a-systematic-review
#10
Alba Manuel-Vazquez, José Manuel Ramia, Raquel Latorre-Fragua, Ainhoa Valle-Rubio, Vladimir Arteaga-Peralta, Carmen Ramiro-Pérez, Roberto de la Plaza-Llamas
OBJECTIVES: This study aimed to identify factors that explain the association of intraductal papillary mucinous neoplasms-pancreatic neuroendocrine tumors (IPMNs-PNETs), radiological characteristics, and factors that might guide therapy. METHODS: We performed a systematic review of the literature to search for articles on concurrent IPMN-PNET, mixed endocrine-exocrine pancreatic tumors, and/or PNET with an intraductal growth pattern. RESULTS: A review of the literature suggests that there is some confusion about association of IPMNs-PNETs...
May 2018: Pancreas
https://www.readbyqxmd.com/read/29668669/pancreatic-neuroendocrine-neoplasms-a-role-of-laparoscopy-in-surgical-treatment-review
#11
Jacek Szeliga, Marek Jackowski
Pancreatic neuroendocrine neoplasms (PNENs) are extremely rare neoplasms of the pancreas. They originate from pancreatic islet cells, and from the very beginning, cancer cells may or may not show hormone hypersecretion. Currently, surgical treatment is the only therapeutic method that significantly prolongs life expectancy, and in such cases it is a method of choice. In the paper, a review of literature based on the Medline database and including mainly the period of 2013 to 2017 was performed. In each case an operating surgeon is responsible for selection of a method used for surgical treatment...
April 17, 2018: Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
https://www.readbyqxmd.com/read/29666945/carbonic-anhydrase-9-expression-in-well-differentiated-pancreatic-neuroendocrine-neoplasms-might-be-associated-with-aggressive-behavior-and-poor-survival
#12
Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
Well-differentiated pancreatic neuroendocrine neoplasms/tumors (PanNETs) are rare neoplasms with diverse clinical behavior. Biomarker discovery is important for predicting clinical course and prognosis of PanNET patients. Carbonic anhydrase 9 (CA9) and vimentin are hypoxia and epithelial-mesenchymal transition-related proteins of which expression in many carcinomas has been associated with poor prognosis, but their significance in PanNET has yet to be determined. We assessed CA9 and vimentin expression in 164 PanNETs and compared this with clinicopathologic characteristics...
April 18, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29649302/identifying-tumor-in-pancreatic-neuroendocrine-neoplasms-from-ki67-images-using-transfer-learning
#13
Muhammad Khalid Khan Niazi, Thomas Erol Tavolara, Vidya Arole, Douglas J Hartman, Liron Pantanowitz, Metin N Gurcan
The World Health Organization (WHO) has clear guidelines regarding the use of Ki67 index in defining the proliferative rate and assigning grade for pancreatic neuroendocrine tumor (NET). WHO mandates the quantification of Ki67 index by counting at least 500 positive tumor cells in a hotspot. Unfortunately, Ki67 antibody may stain both tumor and non-tumor cells as positive depending on the phase of the cell cycle. Likewise, the counter stain labels both tumor and non-tumor as negative. This non-specific nature of Ki67 stain and counter stain therefore hinders the exact quantification of Ki67 index...
2018: PloS One
https://www.readbyqxmd.com/read/29629846/molecular-profiling-of-pancreatic-neuroendocrine-tumors-pnets-and-the-clinical-potential
#14
Massimiliano Camilli, Konstantinos Papadimitrio, Amanda Nogueira, Lorena Incorvaia, Antonio Galvano, Federica D'Antonio, Jose Ferri, Daniele Santini, Nicola Silvestris, Antonio Russo, Marc Peeters, Christian Rolfo
Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations. Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these...
April 9, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29629315/surgical-resection-of-neuroendocrine-tumors-of-the-pancreas-pnets-by-minimally-invasive-surgery-the-laparoscopic-approach
#15
REVIEW
Tomoki Shirota, Yuichi Nagakawa, Yatsuka Sahara, Chie Takishita, Yosuke Hijikata, Yuichi Hosokawa, Tetsushi Nakajima, Hiroaki Osakabe, Kenji Katsumata, Akihiko Tsuchida
Neuroendocrine tumors of the pancreas (pNETs) are a rare group of neoplasms that originate from the endocrine portion of the pancreas. Tumors that either secrete or do not secrete compounds, resulting in symptoms, can be classified as functioning and non-functioning pNETs, respectively. The prevalence of such tumors has recently increased due to the use of more sensitive imaging techniques, such as multidetector computed tomography, magnetic resonance imaging and endoscopic ultrasound. The biological behavior of pNETs varies widely from indolent, well-differentiated tumors to those that are far more aggressive...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29629314/surgical-resection-of-pancreatic-neuroendocrine-neoplasm-by-minimally-invasive-surgery-the-robotic-approach
#16
REVIEW
Roxanne Y A Teo, Brian K P Goh
Over the past decade, there has been increasing adoption of minimally invasive pancreatic surgery world-wide and this has naturally expanded to the management of pancreatic neuroendocrine neoplasms (PNENs). More recently, robotic pancreatic surgery (RPS) was introduced to overcome the limitations during laparoscopic pancreatic surgery (LPS). Due to the relative rarity of PNEN and the novelty of minimally invasive pancreatic surgery in particular RPS today, the evidence for robotic surgery in PNENs remains extremely limited...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29623746/synchronous-pancreatic-serous-cystic-neoplasm-and-duodenal-neuroendocrine-tumor-case-report-and-review-of-the-literature
#17
Ann Brinch Madelung, Sönke Detlefsen
Simultaneous presence of pancreatic serous cystic neoplasms and neuroendocrine neoplasms is rare. We present a case with the incidental finding of a duodenal neuroendocrine tumor (NET) with 2 lymph node metastases in a Whipple resection specimen performed to remove a pancreatic cystic neoplasm that postoperatively turned out to represent a serous cystic neoplasm (SCN). The patient was a 75-year-old female. She presented with loss of appetite and weight. Preoperative contrast-enhanced computed tomography scan of the abdomen showed a multicystic lesion in the head of pancreas...
April 1, 2018: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29610023/the-number-of-positive-nodes-accurately-predicts-recurrence-after-pancreaticoduodenectomy-for-nonfunctioning-neuroendocrine-neoplasms
#18
Stefano Partelli, Ammar A Javed, Valentina Andreasi, Jin He, Francesca Muffatti, Matthew J Weiss, Fausto Sessa, Stefano La Rosa, Claudio Doglioni, Giuseppe Zamboni, Christopher L Wolfgang, Massimo Falconi
BACKGROUND: The most appropriate nodal staging for pancreatic neuroendocrine neoplasms (PanNENs) is unclear. Aim of the study was to evaluate the effect of the number of positive lymph nodes on prognosis after pancreaticoduodenectomy for PanNENs. METHODS: A retrospective analysis of pancreaticoduodenectomies for nonfunctioning PanNENs was performed. PanNENs with nodal metastases (N+) were classified into N1 (1 to 3 positive lymph nodes) and N2 (4 or more positive lymph nodes)...
March 17, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29602973/sunitinib-shrinks-net-g3-pancreatic-neuroendocrine-neoplasms
#19
Yuki Mizuno, Atsushi Kudo, Takumi Akashi, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Shinji Tanaka, Ukihide Tateishi, Minoru Tanabe
PURPOSE: The 2017 revised World Health Organization classification of pancreatic neuroendocrine neoplasms classified conventional G3 tumors into well-differentiated (NET-G3) and poorly differentiated (NEC-G3) tumors. However, guidelines for selection of drug therapy were not established in the 2017 revision. This study aimed to elucidate the rates of maximum tumor reduction of sunitinib, progression-free survival, and overall survival in the new classification. METHODS: We investigated the reduction rate over time using computed tomography for 60 patients with unresectable or distant metastatic pancreatic neuroendocrine neoplasms who received 37...
March 30, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29594467/pancreatic-neuroendocrine-tumor-review-of-heterogeneous-spectrum-of-ct-appearance
#20
REVIEW
Nam Ju Lee, Ralph H Hruban, Elliot K Fishman
OBJECTIVE: Pancreatic neuroendocrine tumors (PanNETs) are uncommon pancreatic neoplasms and can be a diagnostic challenge with heterogeneous spectrum of CT appearance. We review CT findings of PanNETs and other mimics. CONCLUSION: PanNETs are typically hypervascular and have avid enhancement on arterial and venous phase images. However, dedicated pancreas protocol may be needed due to their sometimes atypical appearance including transient enhancement. Careful evaluation of CT findings will help differentiate PanNETs from their mimics, and can be used to establish the diagnosis of a PanNETs...
March 28, 2018: Abdominal Radiology
keyword
keyword
29075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"